Johnson & Johnson Vision received FDA clearance for the new CATALYS cOS 6.0 software used with the CATALYS Precision Laser System. Created in collaboration with Cassini Technologies B.V., the software is designed to simplify astigmatism management workﬂow and increase operational efficiency. Features include advanced visualization that provides full-volume, 3D, high-resolution, and streaming OCT imaging.
Aerie Pharmaceuticals will double the impact of donations made to the ASCRS Foundation, up to $30,000 in donations. Donations made previously through annual meeting registration for ASCRS will be included in Aerie’s progress. Secure donations can be made at www.discovaerielive.com. Contributions will be used to support the ASCRS Foundation’s work to provide charitable eye care and support physician education, in the United States and abroad.
Viela Bio received FDA approval Uplizna (inebilizumab-cdon), used for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). Uplizna is indicated for those who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. Uplinza is the first B cell-depleting antibody approved for NMOSD.
The creators of the DocClocker app, which allows patients to receive real-time wait room estimates of their medical providers, announced the app’s new Remote Check-In tool. Using this feature, patients can check in to their appointments from their car, helping to reduce infection by the coronavirus. More information on DocClocker and the Remote Check-In feature can be found at info.docclocker.com/remotecheckininstructions.
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here.